Cases & Deals

Celgene develops European patent portfolio covering protein-bound nanoparticle technology (Nab®)

Client(s) Celgene Corporation

Jones Day represented Celgene Corporation in successfully obtaining numerous European patents relating to one of its platform technologies, namely protein-bound nanoparticles (Nab®). The patents cover pharmaceutical compositions and formulations comprising such nanoparticles, and medical applications thereof including medical conditions, patient populations, and dosage regimens.